← Leaderboards
Douglas A Jabs
Johns Hopkins University
$24,554,490
Attributed
$24,554,490
Total exposure
13
Grants
7
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $2.7M · FY2005–24$5M$3.8M$2.5M$1.3M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
Funding mix
By agency
NIH$24,554,490 · 13
By mechanism
U10$14,428,309 · 3
R01$7,871,459 · 4
UG1$1,233,041 · 1
K24$609,399 · 1
R03$327,000 · 1
M01$85,282 · 3
Top collaborators
No co-investigators on record.
Most similar at Johns Hopkins University
Same institution · by research overlap
- Peter A Campochiaro$21,020,539
- Janet T. Holbrook$51,624,279
- Barbara S Hawkins$9,860,273
- Richard Holubkov$11,946,832
- Laura Ensign$10,004,174
Others in their field
Top investigators on “Blindness”
- Randall J Bateman · Washington University$137,189,188
- John M Lachin · George Washington University$122,970,601
- David M Nathan · Massachusetts Institute Of Technology$118,921,924
- Beth Baseler · Leidos Biomedical Research, Inc.$111,479,515
- Judith S Hochman · New York University School Of Medicine$100,149,457
- Joseph J. Eron · Univ Of North Carolina Chapel Hill$96,562,493
Research focus
BlindnessUveitisInflammationClinical ResearchCytomegalovirus RetinitisClinical TrialsHuman SubjectVisionFollow-UpOpportunistic InfectionsImplantAdverse EffectsTreatment TrialCataractCohortAdrenal Cortex HormonesUnited StatesVisual ImpairmentRisk FactorsPharmaceutical PreparationsImmuneMacular EdemaEpidemiologyCytomegalovirus
Grant awards (73)
Immunologic Determinants of Age-Related Macular Degeneration (AMD)$469,063
R01 · FY2024 · EY · contact PI
Immunologic Determinants of Age-Related Macular Degeneration (AMD)$469,063
R01 · FY2023 · EY · contact PI
ADALIMUMAB VERSUS CONVENTIONAL IMMUNOSUPPRESSION FOR UVEITIS (ADVISE) TRIAL$302,402
UG1 · FY2023 · EY · contact PI
Immunologic Determinants of Age-Related Macular Degeneration (AMD)$426,723
R01 · FY2022 · EY · contact PI
ADALIMUMAB VERSUS CONVENTIONAL IMMUNOSUPPRESSION FOR UVEITIS (ADVISE) TRIAL$166,625
UG1 · FY2022 · EY · contact PI
Immunologic Determinants of Age-Related Macular Degeneration (AMD)$455,858
R01 · FY2021 · EY · contact PI
ADALIMUMAB VERSUS CONVENTIONAL IMMUNOSUPPRESSION FOR UVEITIS (ADVISE) TRIAL$166,625
UG1 · FY2021 · EY · contact PI
ADALIMUMAB VERSUS CONVENTIONAL IMMUNOSUPPRESSION FOR UVEITIS (ADVISE) TRIAL$166,625
UG1 · FY2020 · EY · contact PI
Immunologic determinants of age-related macular degeneration$325,796
R01 · FY2019 · EY · contact PI
ADALIMUMAB VERSUS CONVENTIONAL IMMUNOSUPPRESSION FOR UVEITIS (ADVISE) TRIAL$182,562
UG1 · FY2019 · EY · contact PI
Developing Classification Criteria for the Uveitides$127,308
R01 · FY2019 · EY · contact PI
DEVELOPING CLASSIFICATION CRITERIA FOR THE UVEITIDES$111,351
R01 · FY2019 · EY · contact PI
ADalimumab Versus conventional ImmunoSupprEssion for uveitis (ADVISE) Trial$76,222
UG1 · FY2019 · EY · contact PI
Immunologic Determinants of Age-Related Macular Degeneration$66,603
R01 · FY2019 · EY · contact PI
Developing Classification Criteria for the Uveitides$418,408
R01 · FY2018 · EY · contact PI
Immunologic determinants of age-related macular degeneration$395,664
R01 · FY2018 · EY · contact PI
Macular Edema Treatment Trials Associated with MUST (META-MUST)$277,528
U10 · FY2018 · EY · contact PI
ADalimumab Versus conventional ImmunoSupprEssion for uveitis (ADVISE) Trial$171,980
UG1 · FY2018 · EY · contact PI
MACULAR EDEMA TREATMENT TRIALS ASSOCIATED WITH MUST (META-MUST)$99,151
U10 · FY2018 · EY · contact PI
Immunologic determinants of age-related macular degeneration$404,392
R01 · FY2017 · EY · contact PI
Developing Classification Criteria for the Uveitides$400,107
R01 · FY2017 · EY · contact PI
Macular Edema Treatment Trials Associated with MUST (META-MUST)$361,139
U10 · FY2017 · EY · contact PI
Developing Classification Criteria for the Uveitides$428,590
R01 · FY2016 · EY · contact PI
Immunologic determinants of age-related macular degeneration$402,219
R01 · FY2016 · EY · contact PI
Macular Edema Treatment Trials Associated with MUST (META-MUST)$361,139
U10 · FY2016 · EY · contact PI
Multicenter Uveitis Steroid Treatment (MUST) Trial$24,671
U10 · FY2016 · EY · contact PI
Macular Edema Treatment Trials Associated with MUST (META-MUST)$350,883
U10 · FY2015 · EY · contact PI
Multicenter Uveitis Steroid Treatment (MUST) Trial$335,082
U10 · FY2015 · EY · contact PI
Macular Edema Treatment Trials Associated with MUST (META-MUST)$412,518
U10 · FY2014 · EY · contact PI
Multicenter Uveitis Steroid Treatment (MUST) Trial$335,082
U10 · FY2014 · EY · contact PI
Multicenter Uveitis Steroid Treatment (MUST) Trial$335,082
U10 · FY2013 · EY · contact PI
Studies of Ocular Complications of AIDS - Chairman's Office$866,241
U10 · FY2012 · EY · contact PI
Multicenter Uveitis Steroid Treatment (MUST) Trial$336,204
U10 · FY2012 · EY · contact PI
Studies of Ocular Complications of AIDS - Chairman's Office$763,685
U10 · FY2011 · EY · contact PI
Studies of Ocular Complications of AIDS - Chairman's Office$759,439
U10 · FY2010 · EY · contact PI
Multicenter Uveitis Steroid Treatment (MUST) Trial$1,265,615
U10 · FY2009 · EY · contact PI
Studies of Ocular Complications of AIDS - Chairman's Office$811,273
U10 · FY2009 · EY · contact PI
Studies of Ocular Complications of AIDS - Chairman's Office$433,381
U10 · FY2009 · EY · contact PI
Studies of Ocular Complications of AIDS - Chairman's Office$147,817
U10 · FY2009 · EY · contact PI
Studies of Ocular Complications of AIDS - Chairman's Office$422,169
U10 · FY2008 · EY · contact PI
Multicenter Uveitis Steroid Treatment (MUST) Trial$419,705
U10 · FY2008 · EY · contact PI
Studies of Ocular Complications of AIDS$522,348
U10 · FY2007 · EY · contact PI
Multicenter Uveitis Steroid Treatment (MUST) Trial$409,603
U10 · FY2007 · EY · contact PI
Studies of Ocular Complications of AIDS$501,059
U10 · FY2006 · EY · contact PI
Multicenter Uveitis Steroid Treatment (MUST) Trial$398,827
U10 · FY2006 · EY · contact PI
ANALYSIS OF CYSTOID MACULAR EDEMA AFTER CATARACT SURGERY$1,233
M01 · FY2006 · RR · contact PI
Studies of Ocular Complications of AIDS$489,939
U10 · FY2005 · EY
Multicenter Uveitis Steroid Treatment (MUST) Trial$359,608
U10 · FY2005 · EY
Analysis of Viral Resistance in CMV Retinitis$163,500
R03 · FY2005 · EY
CMV RETINITIS$37,193
M01 · FY2005 · RR
Studies of Ocular Complications of AIDS$487,138
U10 · FY2004 · EY
Multicenter Uveitis Steroid Treatment (MUST) Trial$365,445
U10 · FY2004 · EY
Analysis of Viral Resistance in CMV Retinitis$163,500
R03 · FY2004 · EY
MENTORED FELLOWSHIP--UVEITIS AND CLINICAL INVESTIGATION$125,052
K24 · FY2004 · EY
CMV Retinitis$46,856
M01 · FY2004 · RR
Studies of Ocular Complications of AIDS$468,653
U10 · FY2003 · EY
MENTORED FELLOWSHIP--UVEITIS AND CLINICAL INVESTIGATION$124,437
K24 · FY2003 · EY
CMV RETINITIS AND VIRAL RESISTANCE$117,285
R01 · FY2003 · EY
CMV RETINITIS AND VIRAL RESISTANCE$715,128
R01 · FY2002 · EY
OCULAR COMPLICATIONS OF AIDS$453,147
U10 · FY2002 · EY
MENTORED FELLOWSHIP--UVEITIS AND CLINICAL INVESTIGATION$123,838
K24 · FY2002 · EY
ACTG 350--ORAL AND INTRAOCULAR GANCICLOVIR AND INTRAVENOUS CIDOFOVIR$0
M01 · FY2002 · RR
CMV RETINITIS AND VIRAL RESISTANCE$696,653
R01 · FY2001 · EY
OCULAR COMPLICATIONS OF AIDS$445,649
U10 · FY2001 · EY
OCULAR IMMUNOPATHOLOGY IN AUTOIMMUNE MODELS$383,748
R01 · FY2001 · EY
MENTORED FELLOWSHIP--UVEITIS AND CLINICAL INVESTIGATION$123,256
K24 · FY2001 · EY
ACTG 350--ORAL AND INTRAOCULAR GANCICLOVIR AND INTRAVENOUS CIDOFOVIR$0
M01 · FY2001 · RR
CMV RETINITIS AND VIRAL RESISTANCE$678,719
R01 · FY2000 · EY
OCULAR COMPLICATIONS OF AIDS$409,089
U10 · FY2000 · EY
OCULAR IMMUNOPATHOLOGY IN AUTOIMMUNE MODELS$348,843
R01 · FY2000 · EY
MENTORED FELLOWSHIP--UVEITIS AND CLINICAL INVESTIGATION$112,816
K24 · FY2000 · EY
OCULAR IMMUNOPATHOLOGY IN AUTOIMMUNE MODELS$29,938
R01 · FY2000 · EY
ACTG 350--ORAL AND INTRAOCULAR GANCICLOVIR AND INTRAVENOUS CIDOFOVIR$0
M01 · FY2000 · RR